EPIX חוב כולל להון ESSA Pharma Inc.

The price evolution chart on GURU.Markets highlights the connection of ESSA Pharma Inc. (EPIX) with oncology centers for new drug trials, with the individual debt-to-equity ratio standing at 0.00. The business relies on the development of EPI-7386, which suppresses tumors in cases of resistance. ESSA Pharma Inc. (EPIX) also protects its developments with patents, competing in the field of therapies for female and male malignancies.

The total debt-to-equity ratio measures the proportion of borrowed funds within the balance sheet structure, determining the degree of financial autonomy and the company's resilience to credit risks. By analyzing the historical ratio of total debt to equity, one can assess the ability of ESSA Pharma Inc. (EPIX) to finance the diversification of production bases for drug supply without excessive debt leverage, which confirms the fundamental reliability of the business.